Pharmacogenomics implementation across multiple clinic settings: a qualitative evaluation.

IF 1.9 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Pharmacogenomics Pub Date : 2023-11-01 Epub Date: 2023-11-17 DOI:10.2217/pgs-2023-0179
Sarah A Shue, Elizabeth Rowe, Lauren A Bell, Teresa Damush, Alexis DeLong, Tayler Gowan, Todd Skaar, David Haggstrom
{"title":"Pharmacogenomics implementation across multiple clinic settings: a qualitative evaluation.","authors":"Sarah A Shue, Elizabeth Rowe, Lauren A Bell, Teresa Damush, Alexis DeLong, Tayler Gowan, Todd Skaar, David Haggstrom","doi":"10.2217/pgs-2023-0179","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To advance clinical adoption and implementation of pharmacogenomics (PGx) testing, barriers and facilitators to these efforts must be understood. This study identified and examined barriers and facilitators to active implementation of a PGx program across multiple clinic settings in an academic healthcare system. <b>Materials & methods:</b> 28 contributors to the PGx implementation (e.g., clinical providers, informatics specialists) completed an interview to elicit their perceptions of the implementation. <b>Results:</b> Qualitative analysis identified several barriers and facilitators that spanned different stages of the implementation process. Specifically, unclear test payment mechanisms, decision support tool development, rigid workflows and provider education were noted as barriers to the PGx implementation. A multidisciplinary implementation team and leadership support emerged as key facilitators. Furthermore, participants also suggested strategies to overcome or maintain these factors. <b>Conclusion:</b> Assessing real-world implementation perceptions and suggested strategies from a range of implementation contributors facilitates a more comprehensive framework and best-practice guidelines for PGx implementation.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To advance clinical adoption and implementation of pharmacogenomics (PGx) testing, barriers and facilitators to these efforts must be understood. This study identified and examined barriers and facilitators to active implementation of a PGx program across multiple clinic settings in an academic healthcare system. Materials & methods: 28 contributors to the PGx implementation (e.g., clinical providers, informatics specialists) completed an interview to elicit their perceptions of the implementation. Results: Qualitative analysis identified several barriers and facilitators that spanned different stages of the implementation process. Specifically, unclear test payment mechanisms, decision support tool development, rigid workflows and provider education were noted as barriers to the PGx implementation. A multidisciplinary implementation team and leadership support emerged as key facilitators. Furthermore, participants also suggested strategies to overcome or maintain these factors. Conclusion: Assessing real-world implementation perceptions and suggested strategies from a range of implementation contributors facilitates a more comprehensive framework and best-practice guidelines for PGx implementation.

药物基因组学实施跨多个诊所设置:定性评价。
目的:为了促进药物基因组学(PGx)检测的临床采用和实施,必须了解这些努力的障碍和促进因素。本研究确定并检查了在学术医疗保健系统中跨多个诊所设置积极实施PGx计划的障碍和促进因素。材料与方法:28位参与PGx实施的贡献者(例如,临床提供者,信息学专家)完成了一次访谈,以引出他们对实施的看法。结果:定性分析确定了跨越实施过程不同阶段的几个障碍和促进因素。具体来说,不明确的测试支付机制、决策支持工具开发、严格的工作流程和提供者教育被认为是PGx实施的障碍。多学科实施团队和领导支持成为关键的推动者。此外,与会者还提出了克服或维持这些因素的策略。结论:评估现实世界的实施看法和来自一系列实施贡献者的建议策略有助于为PGx实施提供更全面的框架和最佳实践指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacogenomics
Pharmacogenomics 医学-药学
CiteScore
3.40
自引率
9.50%
发文量
88
审稿时长
4-8 weeks
期刊介绍: Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信